Faster-Made Cancer-Fighting cells tested in major lymphoma trial
NCT ID NCT06561425
Summary
This study is testing an experimental CAR-T cell therapy called GLPG5101 for people whose B-cell non-Hodgkin lymphoma has come back or hasn't responded to other treatments. The goal is to find the safest and most effective dose and see if this new therapy, which is made at the treatment center, can help control the cancer. It will involve about 274 participants with different subtypes of lymphoma.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Academisch Medisch Centrum
Amsterdam, 1105 AZ, Netherlands
-
Antwerp University Hospital
Edegem, 2650, Belgium
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
-
CHU De Liège
Liège, 4000, Belgium
-
Cliniques Universitaires Saint-Luc
Woluwe-Saint-Lambert, 1200, Belgium
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
Rotterdam, 3015 GD, Netherlands
-
Leiden University Medical Center
Leiden, 2333 ZA, Netherlands
-
Tufts Medical Center
Boston, Massachusetts, 02111, United States
-
UZ Leuven
Leuven, 3000, Belgium
Conditions
Explore the condition pages connected to this study.